PURPOSE: Positron emission tomography (PET) with (18)F-fluorodeoxyglucose (FDG) has been widely used in the management of colorectal cancer (CRC). However, the relationship between FDG accumulation and KRAS/BRAF mutations has not yet been investigated. The purpose of this study was to investigate whether KRAS/BRAF mutations affect FDG accumulation in CRC. EXPERIMENTAL DESIGN: Retrospective analysis was conducted in 51 patients with CRC who underwent FDG-PET/computed tomographic (CT) scans for staging before primary tumor resection. The maximum standardized uptake value (SUV(max)) for the primary tumor and the tumor-to-liver ratio (TLR) were calculated from FDG accumulation and compared between KRAS/BRAF mutated and wild-type groups. Expression levels of glucose transporter-1 (GLUT1) and hexokinase type-II (HXK-II) were assessed by immunohistochemical analysis. RESULTS: Both SUV(max) and TLR were significantly higher in the KRAS/BRAF-mutated group compared with the wild-type group (P = 0.006 and 0.001, respectively). Multivariate analysis indicated that SUV(max) and TLR remained significantly associated with KRAS/BRAF mutations (P = 0.016 and 0.01, respectively). KRAS/BRAF status could be predicted with an accuracy of 75% when a SUV(max) cutoff value of 13 or 14 was used. GLUT1 expression in cancer cells was positively correlated with FDG accumulation and KRAS/BRAF status whereas HXK-II expression was not. CONCLUSION: FDG accumulation was higher in CRC with KRAS/BRAF mutations. FDG-PET/CT scans may be useful for predicting the KRAS/BRAF status of patients with CRC and thus aid in determination of therapeutic strategies for patients with CRC.
PURPOSE: Positron emission tomography (PET) with (18)F-fluorodeoxyglucose (FDG) has been widely used in the management of colorectal cancer (CRC). However, the relationship between FDG accumulation and KRAS/BRAF mutations has not yet been investigated. The purpose of this study was to investigate whether KRAS/BRAF mutations affect FDG accumulation in CRC. EXPERIMENTAL DESIGN: Retrospective analysis was conducted in 51 patients with CRC who underwent FDG-PET/computed tomographic (CT) scans for staging before primary tumor resection. The maximum standardized uptake value (SUV(max)) for the primary tumor and the tumor-to-liver ratio (TLR) were calculated from FDG accumulation and compared between KRAS/BRAF mutated and wild-type groups. Expression levels of glucose transporter-1 (GLUT1) and hexokinase type-II (HXK-II) were assessed by immunohistochemical analysis. RESULTS: Both SUV(max) and TLR were significantly higher in the KRAS/BRAF-mutated group compared with the wild-type group (P = 0.006 and 0.001, respectively). Multivariate analysis indicated that SUV(max) and TLR remained significantly associated with KRAS/BRAF mutations (P = 0.016 and 0.01, respectively). KRAS/BRAF status could be predicted with an accuracy of 75% when a SUV(max) cutoff value of 13 or 14 was used. GLUT1 expression in cancer cells was positively correlated with FDG accumulation and KRAS/BRAF status whereas HXK-II expression was not. CONCLUSION:FDG accumulation was higher in CRC with KRAS/BRAF mutations. FDG-PET/CT scans may be useful for predicting the KRAS/BRAF status of patients with CRC and thus aid in determination of therapeutic strategies for patients with CRC.
Authors: Claudio V Sole; Felipe A Calvo; Carlos Ferrer; Emilio Alvarez; Jose L Carreras; Enrique Ochoa Journal: Eur J Nucl Med Mol Imaging Date: 2014-10-01 Impact factor: 9.236
Authors: Xinggang Wu; Mikyung Park; Dilara A Sarbassova; Haoqiang Ying; Min Gyu Lee; Rajat Bhattacharya; Lee Ellis; Christine B Peterson; Mien-Chie Hung; Hui-Kuan Lin; Rakhmetkazhi I Bersimbaev; Min Sup Song; Dos D Sarbassov Journal: Int J Cancer Date: 2019-10-08 Impact factor: 7.396
Authors: Harrison X Bai; Ashley M Lee; Li Yang; Paul Zhang; Christos Davatzikos; John M Maris; Sharon J Diskin Journal: Br J Radiol Date: 2016-02-11 Impact factor: 3.039
Authors: Carlos Caicedo; Maria Jose Garcia-Velloso; Maria Dolores Lozano; Tania Labiano; Carmen Vigil Diaz; Jose Maria Lopez-Picazo; Alfonso Gurpide; Javier J Zulueta; Javier Zulueta; Jose Angel Richter Echevarria; Jose Luis Perez Gracia Journal: Eur J Nucl Med Mol Imaging Date: 2014-07-03 Impact factor: 9.236
Authors: Stephen S F Yip; John Kim; Thibaud P Coroller; Chintan Parmar; Emmanuel Rios Velazquez; Elizabeth Huynh; Raymond H Mak; Hugo J W L Aerts Journal: J Nucl Med Date: 2016-09-29 Impact factor: 10.057